Back to News
Market Impact: 0.25
Capricor Therapeutics, Inc. (CAPR) Shareholders Who Lost Money Have Opportunity to Lead Securities Fraud Lawsuit
Source: PR Newswire
Legal & LitigationHealthcare & Biotech
The Law Offices of Howard G. Smith announced an opportunity for investors with substantial losses in Capricor Therapeutics to lead a securities-fraud class action lawsuit. The notice signals litigation risk for the biotech company, though the excerpt provides no allegations, claimed damages, class period, or operational impact.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
moderately negative
Sentiment Score
-0.45
Ticker Sentiment
CAPR-0.85
More News
- California AG Says Paramount-WBD Merger Would Hurt the State
- Halozyme prices $1.3 billion convertible notes offering
- Jana Partners pushes Cooper to replace CEO, weigh asset sales- WSJ
- UN fact-finding mission says US committed possible war crimes in Iran
- FDA approves Ultragenyx’s Fayuvi for Sanfilippo syndrome Type A
- Paramount is getting an assist from a key California pol as it defends its Warner merger against AG Rob Bonta
From AllMind Research
- Anthropic IPO Preview: Valuation, Timing, and What to Watch
- Shein After the IPO: Venue, Valuation, and What Must Be Proved
- What AI Research Tools Should a Small Hedge Fund Buy First?
- Alternative Data Due Diligence for Institutional Investors
- Introducing AllMind: A New Data & AI Workspace for Institutional Investors